GW on fire: PhI­II epilep­sy da­ta sig­nals suc­cess ahead for first CBD drug

Im­age: Justin Gov­er, GW Phar­ma

The British com­pa­ny shoot­ing to be the first to launch a drug de­rived from the cannabis plant just got a big nod from the sci­en­tif­ic com­mu­ni­ty, paving the way for what could be one of the biggest block­buster launch­es of the year.

Peer-re­viewed jour­nal The Lancet pub­lished Phase III da­ta on GW Phar­ma­ceu­ti­cals’ cannabid­i­ol med Epid­i­olex, which was stud­ied in a kind of pe­di­atric epilep­sy called Lennox-Gas­taut syn­drome (LGS).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.